VOR33-CLL1+VCAR33-CLL1 Treatment System / Vor Biopharma - LARVOL DELTA

Vor Bio Announces $55.6 Million Private Placement (GlobeNewswire) - "Vor Bio...today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the PIPE) that is expected to result in gross proceeds of approximately $55.6 million, before deducting placement agent fees and other expenses...Vor Bio expects to use net proceeds from the PIPE to fund clinical and preclinical development of its pipeline candidates and for general corporate purposes....Vor Bio expects to announce updated clinical data from the Phase 1/2 VBP301 trial of VCAR33^ALLO in the first half of 2025 and updated clinical data from the Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025."

Financing • P1/2 data • Acute Myelogenous Leukemia • Myelodysplastic Syndrome

Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update (GlobeNewswire) - "Upcoming Milestones: (i) In-house clinical manufacturing facility fully operational in 2022; (ii) VOR33 + VCAR33 Treatment System IND submission expected following initial clinical data from the VBP101 clinical trial and the VCAR33ALLO program."

Commercial • IND • Hematological Malignancies • Oncology

Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update (GlobeNewswire) - "VOR33-CLL1 + VCAR33-CLL1 Treatment System:...Knocking out CD33 and CLL-1 through gene editing offers a promising new approach to treating patients with AML using Vor Bio’s novel eHSC platform, which can be combined with a multi-specific CAR-T approach. The Company plans to share preclinical data on this approach at upcoming scientific meetings in 2022."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology